Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Aug;61(8):1029-1039.
doi: 10.1007/s00592-024-02282-5. Epub 2024 Apr 29.

Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies

Affiliations
Meta-Analysis

Diabetes as a risk factor for pneumococcal disease and severe related outcomes and efficacy/effectiveness of vaccination in diabetic population. Results from meta-analysis of observational studies

Giovanni Antonio Silverii et al. Acta Diabetol. 2024 Aug.

Abstract

Aims: To collect all available evidence on the effect of diabetes mellitus (DM) as a risk factor for pneumococcal disease incidence and related complications, and on the efficacy/effectiveness of vaccines in patients with DM.

Methods: Two distinct systematic searches on MEDLINE, Cochrane, ClinicalTrials.gov and EMBASE databases were performed, one for each meta-analysis, collecting all observational (cohort and case-control) studies and randomized clinical trials performed on humans up to June 1st, 2023.

Results: We retrieved 36 observational studies comparing risk for pneumococcal disease and related complications in people with or without DM, and 11 studies (1 randomized clinical trial and 10 observational studies) assessing conjugated and polysaccaridic vaccines efficacy/effectiveness on preventing such outcomes. People with DM were at higher risk for Invasive Pneumococcal Disease (unadjusted OR 2.42 [2.00; 2.92]); Case-Fatality Rate (unadjusted OR 1.61 [1.25; 2.07], Pneumococcal pneumonia (unadjusted OR 2.98 [2.76; 3.22), and Intensive care unit admission for pneumococcal disease (unadjusted OR 2.09 [1.20; 3.66]). In diabetic individuals vaccinated with conjugated vaccine, incidence of pneumonia specific for vaccine type in a clinical trial (OR 0.237 [0.008; 0.704]), and hospitalization for overall pneumonia during the year following the polysaccharide vaccination in observational studies (unadjusted OR 0.63 [0.45-0.89]) were significantly lower in comparison with unvaccinated DM subjects, with no significant differences for other outcomes.

Conclusions: People with diabetes mellitus are at higher risk for less favourable course of pneumococcal disease and should be therefore targeted in vaccination campaigns; more evidence needs to be collected on vaccination outcomes in people with diabetes.

Keywords: Diabetes mellitus; Pneumococcal disease; Pneumococcal vaccination.

PubMed Disclaimer

Conflict of interest statement

GG declares grants from Sanofi Pasteur MSD, GSK Biologicals SA, Pfizer, Sanofi Pasteur, MSD Italy, Emergent BioSolutions, Moderna, Novavax and Seqirus for taking part to advisory boards, expert meetings, for acting as speaker and/or organizer of meetings/congresses and as principal investigator and chief of O.U. in RCTs. All the other authors have no conflict of interest to disclose directly related to this manuscript.

Figures

Fig. 1
Fig. 1
Difference in risk for invasive pneumococcal disease (IPD) between people with or without diabetes mellitus. (IV = inverse variance, CI = confidence interval, SE = standard error); Panel A, Unadjusted OR; Panel B, Adjusted OR)
Fig. 2
Fig. 2
Difference in risk for case-fatality ratio (CFR) between people with or without diabetes mellitus. (IV = inverse variance, CI = confidence interval, SE = standard error); Panel A, Unadjusted OR; Panel B, Adjusted OR)
Fig. 3
Fig. 3
Differences in pneumonia hospitalizations between vaccinated or unvaccinated patients with diabetes (forest plot; IV = inverse variance random = random effects CI = confidence interval)

References

    1. Jain S, Self WH, Wunderink RG et al (2015) Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:415–427. 10.1056/NEJMoa1500245 10.1056/NEJMoa1500245 - DOI - PMC - PubMed
    1. Kyaw MH, Rose CE Jr, Fry AM et al (2005) The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 192:377–386. 10.1086/431521 10.1086/431521 - DOI - PubMed
    1. Smith SA, Poland GA (2000) Use of influenza and pneumococcal vaccines in people with diabetes. Diabetes Care 23:95–108. 10.2337/diacare.23.1.95 10.2337/diacare.23.1.95 - DOI - PubMed
    1. Farrar JL, Childs L, Ouattara M et al (2023) Systematic review and meta-analysis of the efficacy and effectiveness of pneumococcal vaccines in adults. Pathogens 12:732. 10.3390/pathogens12050732 10.3390/pathogens12050732 - DOI - PMC - PubMed
    1. Huijts SM, Van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM (2017) Post-hoc analysis of a randomized controlled trial: diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly. Vaccine 35:4444–4449. 10.1016/j.vaccine.2017.01.071 10.1016/j.vaccine.2017.01.071 - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources